Cargando…

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This automated IHC assay has been analytically verified and validated using Dako’s autostainer Link 48 and 22C3 mouse anti-PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roach, Charlotte, Zhang, Nancy, Corigliano, Ellie, Jansson, Malinka, Toland, Grant, Ponto, Gary, Dolled-Filhart, Marisa, Emancipator, Kenneth, Stanforth, Dave, Kulangara, Karina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957959/ https://www.ncbi.nlm.nih.gov/pubmed/27333219 http://dx.doi.org/10.1097/PAI.0000000000000408

Ejemplares similares

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy()
por: Sorensen, Steffen Filskov, et al.
Publicado: (2016)

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
por: Cho, Jong Ho, et al.
Publicado: (2018)

Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation
por: Emerson, John W., et al.
Publicado: (2008)

Computational and Bioinformatics Frameworks for Next-Generation Whole Exome and Genome Sequencing
por: Dolled-Filhart, Marisa P., et al.
Publicado: (2013)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
por: Chow, Laura Q.M., et al.
Publicado: (2016)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
por: Kalpakoff, Megan, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
por: Phillips, Therese, et al.
Publicado: (2018)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Effect of physical activity on body condition in Swedish companion dogs
por: Ringmark, Sara, et al.
Publicado: (2015)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2012)

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer
por: Kang, Sulim, et al.
Publicado: (2022)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
por: Inge, L.J., et al.
Publicado: (2020)

Immunohistochemistry
por: HAWES, DEBRA, et al.
Publicado: (2009)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
por: Na, Zhenkun, et al.
Publicado: (2017)

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
por: Horita, Shoichiro, et al.
Publicado: (2016)

Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry
por: Tavares, Ana Beatriz M. L. A., et al.
Publicado: (2018)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

SAT-242 Isolated Adrenocorticotropic Hormone Deficiency Secondary to the PD-1 Inhibitor Pembrolizumab
por: Mathew, Justin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6gphpc4av3blui00c2vpodrffj